Imunon Inc Stock Price, News & Analysis

IMUNON (NASDAQ: IMNN) is hosting an R&D Day on September 18th at the Harvard Club in New York City from 10:00 a.m. to 1:00 p.m. Eastern time. The event follows the announcement of top-line data from their randomized Phase II Ovation 2 Study, which showed an 11.1-month increase in median overall survival for advanced ovarian cancer patients, representing a 35% improvement in survival.

The program will feature ovarian cancer experts, principal investigators from the OVATION 2 Study, and discussions on IMNN-001's potential role in treating advanced ovarian cancer. Management will also discuss next steps for their immunotherapy and prospects for extending patient survival. While in-person attendance is encouraged, a virtual option will be available. Program details and RSVP information will be provided soon.

IMUNON (NASDAQ: IMNN) reported positive topline results from its Phase 2 OVATION 2 Study of IMNN-001 in advanced ovarian cancer. Key highlights include:

- 11.1 month increase in median overall survival (OS) compared to standard-of-care
- 35% improvement in survival (hazard ratio 0.74) in intent-to-treat population
- 15.7 month increase in median OS for patients receiving at least 20% of specified treatments
- 56% improvement in survival (hazard ratio 0.64) for per-protocol population

The company plans to hold an End-of-Phase 2 meeting with the FDA to discuss a Phase 3 study protocol, anticipated to begin in Q1 2025. IMUNON also reported financial results, with a net loss of $4.8 million for Q2 2024 and $9.7 million for H1 2024. The company raised $10 million in a registered direct offering, extending its cash runway into Q3 2025.

IMUNON, Inc. (NASDAQ: IMNN) has announced a conference call scheduled for August 14, 2024, at 11:00 a.m. ET to discuss its second quarter 2024 financial results and provide updates on its clinical development programs. The company will focus on two key areas:

1. IMNN-001: A DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for first-line, locally advanced-stage ovarian cancer.

2. PlaCCine modality: A proprietary DNA plasmid and synthetic DNA delivery technology for expressing pathogen antigens in next-generation vaccine development.

Interested parties can join the call via phone or webcast, with replay options available until August 28, 2024.

IMUNON (NASDAQ: IMNN) has announced a $10 million registered direct offering of its common stock, priced at-the-market under Nasdaq rules. The offering includes 5,000,000 registered shares at $2.00 per share, along with unregistered warrants to purchase up to 5,000,000 additional shares. The warrants have an exercise price of $2.00 per share and are exercisable immediately for 5.5 years. The company expects to close the offering around August 1, 2024, with H.C. Wainwright & Co. as the lead placement agent. IMUNON plans to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to a previously filed and effective shelf registration statement.

IMUNON announces positive topline results from the Phase 2 OVATION 2 Study of IMNN-001 in patients with advanced ovarian cancer. Key highlights include:

- 11.1-month increase in median overall survival (OS) compared to standard-of-care in the intent-to-treat population

- 15.7-month increase in median OS for patients receiving at least 20% of specified treatments

- Hazard ratio of 0.41 for patients also receiving PARP inhibitor therapy

- 3-month improvement in progression-free survival

IMUNON plans to initiate a Phase 3 registrational study in Q1 2025, pending FDA discussions.

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company, is set to announce topline results from its Phase 2 OVATION 2 Study on July 30, 2024, at 8:00 a.m. Eastern time. The study focuses on IMNN-001, the company's DNA-mediated immunotherapy for advanced ovarian cancer. IMNN-001 is an interleukin-12 (IL-12) immunotherapy based on IMUNON's TheraPlas™ technology.

Following the announcement, IMUNON will host an investment community conference call at 8:30 a.m. Eastern time to discuss the results and answer questions. Interested parties can participate by dialing 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll). A live webcast and replay of the call will be available, with the replay accessible until August 13, 2024.

IMUNON has announced the database lock for its Phase 2 OVATION 2 Study, which evaluates IMNN-001 in advanced ovarian cancer. The study, involving 110 patients, is assessing the safety, efficacy, and biological activity of IMNN-001 combined with neoadjuvant chemotherapy (NACT). The primary endpoint is Progression-Free Survival (PFS) and secondary endpoints include Overall Survival (OS). The independent statisticians have received the raw data and will analyze it per the Statistical Analysis Plan. IMUNON expects to release topline results by the end of July 2024. This study will guide the design of a planned Phase 3 trial.

IMUNON (NASDAQ: IMNN) has initiated the Phase 1 clinical trial for its IMNN-101 vaccine, a seasonal COVID-19 vaccine developed using its proprietary PlaCCine® DNA platform. The trial aims to evaluate the safety, tolerability, and immune response of the vaccine in 24 healthy volunteers, divided into three dosage groups. The study follows FDA guidelines to combat the SARS-CoV-2 Omicron XBB1.5 variant. IMUNON's preclinical data show promising results, with over 95% immunogenicity and stability at various temperatures. Topline data is expected by year-end 2024.

IMUNON (NASDAQ: IMNN) announced that an abstract detailing a Phase 2 study involving IMNN-001 combined with bevacizumab (Avastin) and neoadjuvant chemotherapy for advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The presentation will occur on June 3, 2024, during the Gynecologic Cancer session at the event in Chicago, which runs from May 31 to June 4.

Lead investigator Dr. Amir A Jazaeri from The University of Texas MD Anderson Cancer Center will present the study, which aims to evaluate the effect of this combination therapy in newly diagnosed patients. The study is actively recruiting participants in the U.S. and is substantially funded by Break Through Cancer.

According to Dr. Sebastien Hazard, IMUNON’s Chief Medical Officer, the synergy observed between IMNN-001 and bevacizumab in pre-clinical experiments is promising, and the company aims to complete enrollment quickly to address this critical clinical question.